To evaluate the real-world effectiveness of Denosumab compared with Alendronate in reducing fracture risk in women with postmenopausal osteoporosis in the U.S
Latest Information Update: 28 Dec 2022
At a glance
- Drugs Denosumab (Primary) ; Alendronic acid
- Indications Postmenopausal osteoporosis
- Focus Therapeutic Use
Most Recent Events
- 28 Dec 2022 New trial record
- 14 Nov 2022 Results presented at the ACR Convergence 2022